Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi & miRNA

Xianbin Yang's Biography



Xianbin Yang, Director, AM Biotechnologies LLC

Xianbin Yan, bioorganic chemist, graduated from the School of Pharmaceutical Sciences, Beijing Medical University in 1988. Xianbin obtained his Master of Medicine at Beijing Medical University in 1995 and his Ph.D in 1998, after which he became a postdoctoral fellow at the University of Texas Medical Branch (UTMB) in Galveston, Texas, USA. In 2004, Xianbin became a faculty member in the Department of Biochemistry and Molecular Biology at UTMB. He then transitioned to Director of Research and Development at AM Biotechnologies in 2007. He became an adjunct faculty at the University of Houston at Clear Lake in 2008. Xianbin also recently obtained an MBA from the University of Houston at Clear Lake, Texas, USA. Xianbin was the recipient of two awarded and 5 pending patents and the recipient of the James W. McLaughlin Award for Research Excellence in Infection and Immunity at UTMB in 2003. He was the PI for 10 highly competitive awarded grants including one from the UTMB Cancer Research Center, one from the Mike Hogg Foundation, six from National Institute of Health, and two from the National Aeronautics and Space Administration (NASA). In addition, he was awarded two highly selective fellowships to attend the First and Second Meetings of the Oligonucleotide Therapeutics Society in New York in 2005 and 2006, respectively. Xianbin is author or co-author of more than 50 publications and two book chapters.

Xianbin Yang Image

Enabling RNAi Therapeutics Development through Modified siRNA

Thursday, 19 April 2012 at 16:30

Add to Calendar ▼2012-04-19 16:30:002012-04-19 17:30:00Europe/LondonEnabling RNAi Therapeutics Development through Modified siRNASELECTBIOenquiries@selectbiosciences.com

Chemically modified siRNA duplexes with enhanced delivery and improved pharmacokinetics properties are required for therapeutic applications. This presentation, will describe (1) RNA monomers with dual modification chemistries for synthesizing modified siRNAs; (2) the pharmaceutical and biological properties of modified siRNA, and (3) the high potency modified-siRNA gene silencing in vitro and in vivo.


Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonRNAi and miRNASELECTBIOenquiries@selectbiosciences.com